2019
DOI: 10.3390/cancers11091374
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments

Abstract: Epidermal growth factor receptor (EGFR) plays critical roles in cell proliferation, tumorigenesis, and anti-cancer drug resistance. Overexpression and somatic mutations of EGFR result in enhanced cancer cell survival. Therefore, EGFR can be a target for the development of anti-cancer therapy. Patients with cancers, including non-small cell lung cancers (NSCLC), have been shown to response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and anti-EGFR antibodies. However, resistance to these anti-EGFR treatments … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
49
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(51 citation statements)
references
References 180 publications
(186 reference statements)
2
49
0
Order By: Relevance
“…Bioinformatic approach uncovered that the 22-gene signature mainly associated with the PI3K-AKT signaling pathway, the VEGF signaling pathway, EGFR tyrosine kinase inhibitor (EGFR-TKI) resistance, apoptosis, and ubiquitin-mediated proteolysis in LUAD. Interestingly, tons of studies have found that autophagy plays a part in the EGFR-TKI resistance of tumor cells [1114, 35]. EGFR-TKI induces autophagy through the suppression of the PI3K/AKT/mTOR signaling pathway, which in turn saves tumor cells from the harm of EGFR-TKIs [14].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Bioinformatic approach uncovered that the 22-gene signature mainly associated with the PI3K-AKT signaling pathway, the VEGF signaling pathway, EGFR tyrosine kinase inhibitor (EGFR-TKI) resistance, apoptosis, and ubiquitin-mediated proteolysis in LUAD. Interestingly, tons of studies have found that autophagy plays a part in the EGFR-TKI resistance of tumor cells [1114, 35]. EGFR-TKI induces autophagy through the suppression of the PI3K/AKT/mTOR signaling pathway, which in turn saves tumor cells from the harm of EGFR-TKIs [14].…”
Section: Discussionmentioning
confidence: 99%
“…It was also the case with anti-EGFR treatments, as mentioned above. Autophagy inhibitors have been demonstrated to increase the sensitivity of NSCLC cells to EGFR-TKIs [35]. Moreover, the molecular interplay among apoptosis, autophagy, and proteasomal protein degradation pathway are also well documented [38, 44].…”
Section: Discussionmentioning
confidence: 99%
“…In this regard, our previous study has demonstrated that morusin can induce apoptosis in EGFR tyrosine kinase inhibitor-resistant NSCLC cells and treatment-naive NSCLC cells [ 20 ]. Although the current study does not focus on the chemoresistant-overcoming activity of morusin, autophagy has emerged as a potential mechanism involved in drug resistance in NSCLC [ 36 37 ]. Therefore, combined treatment with morusin and autophagy inhibitor might be effective for chemoresistant NSCLC cells.…”
Section: Discussionmentioning
confidence: 99%
“…Under physiological conditions, EGFR-activated PI3K/AKT/mTOR signaling inhibits autophagy, while in tumors received therapies this pathway contribute to resistance via activation of autophagy. However, in tumors with resistance, EGFR targeting may provide us to overcome resistance [120]. As a result, this cross-regulation mediates exosomal-induced autophagy in target cells.…”
Section: Cross-regulation By Akt/mtor Signaling Pathwaymentioning
confidence: 99%